Tag: anti-SARS-CoV-2 plasma product
CSL Behring Australia Commences Development of Treatment for Serious Cases of COVID-19
Media Release
CSL Behring Australia, a subsidiary of CSL Limited, today announced that it will begin immediate onshore development of an anti-SARS-CoV-2 plasma product with...
Featured Article
Data-rich or data-poor: Where should manufacturers focus their AI efforts?
Over the past year, manufacturers worldwide have made significant strides in adopting artificial intelligence technologies, moving beyond the initial hype to tangible implementations that deliver real business value.
